T cell-antigen coupler with various construct optimizations

Patent metadata

Field	Value
Publication number	US-11878035-B2
Application number	US-202318188326-A
Country	US
Kind code	B2
Filing date	Mar 22, 2023
Priority date	Jul 17, 2018
Publication date	Jan 23, 2024
Grant date	Jan 23, 2024

Abstract

A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.

First claim

What is claimed is:

1. An engineered γδT cell comprising an expression vector comprising a nucleic acid encoding a human epidermal growth factor receptor (HER2) T cell-antigen coupler (HER2-TAC) polypeptide having the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 68, or SEQ ID NO: 76, wherein the HER2-TAC polypeptide is expressed by the engineered γδT cell.

2. The engineered γδT cell of claim 1 , wherein the amino acid sequence of SEQ ID NO: 66 is encoded by the nucleic acid sequence of SEQ ID NO: 65, the amino acid sequence of SEQ ID NO: 68 is encoded by the nucleic acid sequence of SEQ ID NO: 67, and the amino acid sequence of SEQ ID NO: 76 is encoded by the nucleic acid sequence of SEQ ID NO: 75.

3. A pharmaceutical composition, comprising the γδT cell of claim 1 , and a pharmaceutically acceptable excipient.

4. A method of providing a cancer immunotherapy for treating a HER2-expressing cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the engineered γδT cell of claim 1 , wherein an antigen binding antibody fragment of the HER2-TAC polypeptide binds to a HER2 antigen expressed by the cancer, wherein administration of said engineered γδT cell results in a reduction in cancer cells in the subject.

5. The method of claim 4 , wherein the cancer is breast cancer, bladder cancer, pancreatic cancer, ovarian cancer, glioblastoma, or gastric cancer.

6. The method of claim 4 , wherein the cancer is a carcinoma, a blastoma, or a sarcoma.

Assignees

• Triumvira Immunologics Usa Inc
• Univ Mcmaster

Inventors

• Bramson Jonathan Lorne
• Helsen Christopher W
• Hammill Joanne Alicia
• Mwawasi Kenneth Anthony

Classifications

• A61K40/4215

  Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30 · CPC title

• A61K40/4211

  CD19 or B4 · CPC title

• A61K40/4205

  Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4 · CPC title

• A61K40/32

  T-cell receptors [TCR] · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title